In the clinical setting, the evaluation of NF-κB in pre- and post-chemotherapy breast cancer samples from patients subjected to neoadjuvant chemotherapy with anthracycline- and/or taxane, showed that activation of NF-κB was associated with chemoresistance. Here, NFKB1 is linked to breast cancer.